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Abstract
Background: Medulloblastomas, embryonal tumors arising in the cerebellum, commonly contain
mutations that activate Wnt signaling. To determine whether increased Wnt signaling in the adult
CNS is sufficient to induce tumor formation, we created transgenic mice expressing either wild-
type or activated β-catenin in the brain.
Methods: Wild-type and mutant human β-catenin transgenes were expressed under the control
of a murine PrP promoter fragment that drives high level postnatal expression in the CNS. Mutant
β-catenin was stabilized by a serine to phenylalanine alteration in codon 37.
Results: Expression of the mutant transgene resulted in an approximately two-fold increase in β-
catenin protein levels in the cortex and cerebellum of adult animals. Immunohistochemical analysis
revealed nuclear β-catenin in hippocampal, cortical and cerebellar neurons of transgenic animals
but not in non-transgenic controls. Tail kinking was observed in some transgenic animals, but no
CNS malformations or tumors were detected.
Conclusions: No tumors or morphologic alterations were detected in the brains of transgenic
mice expressing stabilized β-catenin, suggesting that postnatal Wnt signaling in differentiated
neurons may not be sufficient to induce CNS tumorigenesis.
Background
Medulloblastomas, embryonal neoplasms arising in the
cerebellum, are the most common malignant pediatric
brain tumor. In man, three inherited syndromes associat-
ed with medulloblastomas have been described: Turcot's,
Gorlin's and Li Fraumeni (reviewed in [1]). Li Fraumeni
syndrome is caused by inherited mutations in the p53 tu-
mor suppressor gene. Affected individuals develop a large
spectrum of CNS and extra-CNS neoplasms, including
medulloblastomas [2]. Interestingly, alterations in p53
are relatively rare in sporadic medulloblastomas, with
mutations detected in 5% or less of cases [3,4].
The genes most commonly altered in medulloblastoma
are members of developmental signaling pathways. Gor-
lin's syndrome results from inherited mutations in the
Hedgehog receptor PTCH that constitutively activate the
pathway. Mutations in the Hedgehog pathway members
PTCH, PTCH 2, SUFU and Smo, have all been identified in
sporadic medulloblastomas as well, with approximately
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25% of cases containing mutations affecting these genes
[5–9]. A murine medulloblastoma model was recently de-
veloped by disruption of the PTCH gene, with medullob-
lastoma-like tumors arising in 10–15% of heterozygotes
by 9 months of age [10,11]. Breeding PTCH mice to p53
knockout animals markedly increased tumor incidence.
Mice heterozygous for PTCH and lacking p53 all devel-
oped medulloblastomas by 3 months of age [12].
Turcot's syndrome is caused by germline mutations in the
gene APC, a member of the Wnt signaling pathway. This
developmentally important pathway contains several pro-
teins, including APC, Frizzled, Axin and GSK3, which act
in concert to promote the proteosomal degradation of β-
catenin [13,14]. When APC is rendered inactive by muta-
tion, β-catenin levels rise and the protein moves into the
nucleus where it acts with Tcf/Lef cofactors to regulate
transcription of c-myc, cyclin D and other oncogenes [15].
APC mutations have been identified in medulloblastoma
cell lines and up to 4% of sporadic medulloblastomas
[16,17]. Furthermore, point mutations or small deletions
in β-catenin exon 3 have been identified in 5–10% of spo-
radic medulloblastomas and in supratentorial primitive
neuroectodermal tumors (PNETs) [17–19]. Finally, large
deletions in AXIN were recently found in 12% of sporadic
medulloblastomas [20]. In the absence of Wnt signaling
β-catenin is sequestered in the cytoplasm, and nuclear
translocation of β-catenin has been used to monitor acti-
vation of the Wnt pathway in a number of different tumor
types. We have previously shown that nuclear β-catenin is
present in 18% of sporadic medulloblastomas [18].
The greatly increased incidence of medulloblastomas in
patients inheriting mutations in the APC tumor suppres-
sor gene suggests that activation of Wnt signaling could be
sufficient in some cases to initiate medulloblastoma for-
mation. The mitogenic role played by Wnts in normal
CNS development also supports the concept that the
pathway could promote growth in the brain [21,22]. In
order to test this hypothesis we created transgenic mice in
which the Wnt pathway was aberrantly activated in the
CNS.
In order to avoid possible in utero lethality caused by ex-
cess pathway activity, we used the murine PrP promoter
element to construct our transgenic lines. Wnt signaling is
known to play a critical role in the development of the
brain, and the midbrain and cerebellum do not form in
animals lacking Wnt-1 [23]. Furthermore, targeted disrup-
tion of the frizzled-4 gene results in cerebellar abnormali-
ties in mice [24]. Transgene expression from the PrP
promoter is extremely low during embryonic develop-
ment, with high-level postnatal expression largely restrict-
ed to neurons and glia of the CNS [25]. Transgenic mice
expressing either wild-type or mutant β-catenin were gen-
erated so that a range of pathway activation could be ex-
amined. Mutant β-catenin was stabilized by a serine to
phenylalanine alteration in codon 37, a change found in
human tumors. We hypothesized that increased expres-
sion of wild-type protein might result in modest activa-
tion of the pathway, while expression of mutant,
stabilized protein would increase Wnt signaling activity
more significantly. The mutant β-catenin accumulated in
neuronal nuclei in our transgenic mice, but no tumors or
other microscopic abnormalities were detected. The lack
of aberrant neuronal proliferation in our mice suggests
that differentiated neurons may not be as susceptible to
the mitogenic effects of Wnt signaling as are neuroepithe-
lial progenitor cells [22].
Methods
Cell culture
Medulloblastoma DAOY cells were obtained from the
American Type Culture Collection and maintained in Im-
proved MEM Zn++ Option (Richter's Modification) medi-
um containing supplemented with 20% fetal bovine
serum (Life Technologies, Inc., USA). The TOPFLASH Wnt
reporter plasmid was obtained from Dr. Kenneth Kinzler.
FLAG epitope tagged wild-type and S37F mutant β-caten-
in in pCINeo expression vectors were the kind gifts of Dr.
Patrice Morin [26]. Cells were plated at a density of
300,000 per 60 mm plate. Transient transfections of β-cat-
enin, β-galactosidase and Wnt reporter plasmids were per-
formed using the Fugene reagent 24 hours after initial
plating (Roche Molecular Biochemicals). Cells were har-
vested for reporter assays 48 hours after transfection. All
experiments were performed in quadruplicate. β-galactos-
idase and luciferase activities were measured using stand-
ard techniques. β-galactosidase activity was used to
control for transfection efficiency.
Transgenic mice
Transgene constructs were created using wild-type or S37F
mutant β-catenin cDNAs with 3' FLAG epitope sequences.
β-catenin cDNAs were inserted into the previously de-
scribed pBS/MoPrP.Xho vector and the orientation veri-
fied by sequencing [25]. The resulting construct was
linearized and gel-purified prior to injection into B6/SJL
mouse embryos. Transgenic lines were established using
standard methods at the Johns Hopkins Transgenic Core
Facility. Human β-catenin exon 3 was PCR-amplified
from transgenic mouse DNA and sequenced to verify pres-
ence or absence of the codon 37 mutations. Mice were
maintained on a B6/SJL hybrid background.
DNA was extracted from tail clips by proteinase K diges-
tion followed by ethanol precipitation. The transgene was
detected by PCR amplification of a 200 bp product using
a forward primer located in the β-catenin cDNA sequence
(βcat3pb: 5' TCGTTCTTTTCACTCTGGTGGAT 3') and aBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/33
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reverse primer in the PrP promoter (PrP-S: 5' GTGGATAC-
CCCCTCCCCCAGCCTAGACC 3'). A 750 bp control
band was produced by amplification from the endog-
enous PrP gene using PrP-S and the reverse primer (PrP-
AS: 5' CCTCTTTGTGACTATGTGGACTGATGTCGG 3').
Homozygous null P53 knockout mice (B6.129S2-
Trp53tm1Tyj) were purchased from Jackson Labs and
crossed with β-catenin transgenic mice. Transgenic p53
heterozygous mice were then crossed with non-transgenic
p53 heterozygotes to produce β-catenin transgenic, p53
null mice. p53 genotyping was done by PCR from tail
DNA according to the Jackson Labs Protocol using their
oIMR336, oIMR337, oIMR013 and oIMR014 primers.
Phenotypic analysis
Mouse brains were removed immediately after sacrifice
and fixed for 24–48 hours in 10% buffered formalin.
Brains were sectioned sagitally or coronally and haema-
toxylin and eosin stained slides examined by a pathologist
(CGE or DLH). Complete necropsies were done on mice
that died unexpectedly (DLH).
Western blotting
10% weight/volume protein homogenates were prepared
from mouse brain as previously described [27]. Nuclear
and cytoplasmic protein fractions were prepared with NE-
PER Nuclear and Cytoplasmic Extraction Reagents using
the manufacturer's instructions (Pierce Chemical Co.,
Rockford, IL). HSP90, a cytoplasmic protein, was used to
control for loading, and for separation of nuclear and cy-
toplasmic fractions.
Samples were resolved (20 µg per lane total protein, 12.5
µg nuclear and cytoplasmic fractions) by SDS-PAGE. Pri-
mary antibody incubations were carried out overnight at
4°C. The transgene product was detected in total protein
extracts using a mouse monoclonal anti-FLAG antibody
(Sigma-Aldrich, St. Louis, MO) diluted 1:1000 with a
mouse monoclonal anti-GAPDH antibody (Research Di-
agnostics Inc., Flanders, NJ) diluted 1:150,000 as a load-
ing control. Total β-catenin was detected in nuclear and
cytoplasmic fractions with a mouse monoclonal anti-β-
catenin (E5) antibody (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA) diluted 1:1000. A rabbit polyclonal anti-
hsp90 (H-114) antibody (Santa Cruz) diluted 1:1000 was
used as a control. Primary antibodies were detected with
peroxidase-conjugated anti-mouse or rabbit IgG second-
ary antibodies (KPL, Gaithersburg, MD) diluted 1:2000.
Western Lightning Chemiluminescence Reagent (Perkin
Elmer Life Sciences Inc., Boston, MA) was applied and the
signal was visualized with x-ray film.
Immunohistochemistry
Formalin fixed, paraffin embedded mouse brain sections
were deparaffinized and antigen retrieval was performed
for 1 minute in a pressure cooker with antigen unmasking
solution (Vector Laboratories, Burlingame, CA). Endog-
enous peroxidase activity was quenched with 3% H2O2
for 5 minutes at room temperature. Sections were incubat-
ed for 45 minutes at room temperature with a mouse
monoclonal anti-β-catenin (E5) antibody (Santa Cruz) di-
luted 1:200. The primary antibody was visualized with the
Vectastain Elite ABC mouse kit (Vector Labs).
Results
Transcriptional activity of β-catenin constructs in medul-
loblastoma DAOY cells
In order to evaluate the transcriptional activity of FLAG
epitope-tagged β-catenin in a medulloblastoma cell line,
the S37F and wild-type constructs were introduced into
DAOY cells along with the Wnt pathway TOPFLASH re-
porter. This reporter plasmid contains three optimal TCF
binding sites [28]. TOPFLASH luciferase activity was acti-
vated 41-fold by S37F mutant β-catenin and 3.8 fold by
wild-type β-catenin in DAOY cells (Fig. 1).
β-catenin protein expression in transgenic mice
Five transgenic lines were established, two expressing
wild-type human β-catenin (WT-1,2) and three expressing
human β-catenin stabilized by mutation of the phospho-
rylation site at residue 37 (Mut-1,2,3). Levels of transgenic
protein were evaluated by Western blot using antibodies
directed against a FLAG sequence in the C-terminus of the
transgenic protein (Fig. 2A). Transgenic protein was ex-
pressed at high levels in the brains of WT-1, Mut-1 and
Mut-2 mice and at lower levels in the WT-2 and Mut-3
lines. Protein extracts prepared separately from the cere-
bral cortex and cerebellum/brainstem had similar protein
levels (data not shown). Attempts to localize expression
of the transgenic protein immunohistochemically in
brain tissue sections using anti-FLAG antibodies were not
successful. To evaluate overall expression levels of β-cat-
enin (transgenic and endogenous) Western blots were
probed with an antibody that binds both human and
murine β-catenin. WT-1 brains contained only modestly
increased amounts of protein (data not shown). However,
cerebellum from the Mut-1 and Mut-2 lines contained
50–100% more β-catenin protein than non-transgenic
controls (Fig. 2B). Some variation in β-catenin protein
level was seen between animals, but this was not related
to age and high expression levels were seen at all time
points evaluated (6 weeks to 12 months; data not shown).
Nuclear β-catenin in hippocampus, cortex and cerebellum 
of transgenic mice
To determine whether expression of transgenic β-catenin
resulted in increased Wnt pathway activity we analysedBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/33
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the subcellular distribution of β-catenin in the brain. Nu-
clear translocation of β-catenin is generally associated
with Wnt signaling activity. Nuclear fractionation was per-
formed and the amount of total β-catenin in the cytoplas-
mic and nuclear fractions assayed (Fig. 2B). Stains for the
cytoplasmic protein HSP90 were used to evaluate frac-
tionation and revealed some contamination of the nucle-
ar fractions. Still, the amount of β-catenin appeared
significantly increased in the nuclear fraction of CNS pro-
tein extracts from the Mut-1 transgenic line, and some-
what increased in Mut-2 nuclear fractions.
We also analysed β-catenin distribution immunohisto-
chemically. In non-transgenic mice β-catenin is abundant
in cytoplasm but excluded from hippocampal, cerebellar
or cortical nuclei (Fig. 3A,3C). In contrast, several of the
transgenic lines contained numerous neurons with nucle-
ar protein in the hippocampus, cerebral cortex and cere-
bellum. Consistent with the nuclear fractionation
experiments described above, nuclear β-catenin was most
prominent in the Mut-1 animals. In the cerebellum 20–
40% of the granule cell nuclei were positive, and positive
nuclei were also found scattered throughout the molecu-
lar layer (Fig. 3B). Purkinje cell nuclei were negative. In
the cortex, nuclei of many small to medium sized neurons
were strongly positive (Fig. 3D). Nuclear β-catenin was
only rarely detected in glial cells, mostly those with oli-
godendroglial morphology. Strongly positive nuclei were
also present in the dentate gyrus and pyramidal cell layer
of the hippocampus. Mut-2 animals contained scattered
β-catenin positive nuclei in the hippocampus, cortex and
cerebellum, but fewer than were seen in Mut-1. In Mut-3
animals 20–50% of cerebellar neurons in the granule and
molecular layers contained nuclear β-catenin, and hip-
pocampal cells were occasionally positive, but the cortical
neuronal nuclei were largely negative. The nuclei of hip-
pocampal, cerebellar and cortical neurons in WT-1 and
WT-2 mice were also mostly negative for β-catenin, al-
though occasional weakly positive nuclei were seen in
these two lines. No nuclear staining was seen in these
structures in most non-transgenic animals, suggesting that
weak activation of Wnt signaling may occur with overex-
Figure 1
S37F mutant β-catenin activity in medulloblastoma DAOY cells. Cotransfection of the TOPLASH Wnt reporter and 
FLAG-tagged S37F mutant β-catenin into DAOY cells results in 41-fold higher luciferase activity than transfection of TOP-
FLASH alone. Similar transfections of wild-type β-catenin result in 3.8-fold higher luciferase activity. No luciferase activity was 
detected in cells transfected with pBluescript (Negative Control). (pTF – TOPFLASH plasmid; WT – wild-type).
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pression of wild type β-catenin protein. Nuclear β-catenin
was detected in the thalami and other cortical deep grey
matter loci in both transgenic and non-transgenic ani-
mals.
In order to determine if Wnt signaling was aberrantly ac-
tive in the cerebellar neuroblasts thought to give rise to
some medulloblastomas, β-catenin immunostains were
performed on newborn Mut-1 and Mut-2 animals. Nuclei
in the proliferating external granule cell layer of P0 trans-
genics did not contain β-catenin. Nuclear β-catenin was
also absent from the ventricular zone cells in P0 transgen-
ic animals.
Phenotypic analysis
The most striking phenotype was the "kinking" of tails
seen in lines Mut-1 and Mut-3 (Table 1). A large percent-
age of the Mut-3 animals had kinked tails, while in the
Mut-1 line it was a rare finding. It is not clear why the Mut-
3 line, which has lower levels of transgenic protein in the
cortex, was most susceptible to tail defects. Tail kinks
ranged from single, acute bends to multiple angulations
resembling knots (Fig. 4). Kinked tails were of normal
length or slightly shortened. Radiographic analysis re-
vealed vertebral bodies in the kinked regions to be atten-
uated in size or malformed. Peculiar circling or "waltzing"
behaviors were also noted in many of the transgenic ani-
mals. These animals spun in place or ran repetitively in
tight circles for up to 20 seconds at a time. While the
waltzing was most common in mice expressing mutant β-
catenin, one non-transgenic mouse also exhibited a loose
circling behavior.
Mice from each transgenic line as well as non-transgenic
siblings were observed daily to identify any animals with
signs of tumors or other neurological abnormalities.
However, uncoordinated movements, somnolence, or
poor grooming, as is seen in PTCH animals developing tu-
mors, were never observed. A total of 69 mutant β-catenin
and 35 wild-type β-catenin animals were observed for at
least nine months before being sacrificed (Table 1). Of
these, 41 Mut-1 and Mut-2 animals expressing high levels
of mutant, stabilized β-catenin were observed for over one
year, with 12 animals reaching 15 to 17 months of age.
Animals were sacrificed at the end of the observation pe-
riod and their brains removed, but no tumors or other
gross or microscopic CNS abnormalities were detected.
While a number of transgenic animals died in the first
nine months, the percentage of animals surviving was not
significantly different between the transgenic and non-
transgenic groups (Table 1). Necropsies on animals expir-
ing prior to sacrifice failed to reveal brain tumors or other
CNS alterations. Several of these animals had glomeru-
lonephritis, but overall the causes of death were variable,
and, except for tail kinking, no clear pattern of extra-CNS
defects emerged in the transgenic animals.
No increase in tumorigenesis in p53 mutant animals ex-
pressing transgenic β-catenin
To increase the probability of brain tumor development,
several transgenic lines (WT-1 and Mut-1,2,3) were
crossed onto a p53-deficient background. No brain tu-
mors were identified among the 1 WT-1, 1 Mut-1, 10 Mut-
2 and 2 Mut-3 animals that were p53 null. These animals
all died within 9 months from lymphomas or other extra-
CNS neoplasms known to be associated with abrogation
of p53 function. Brain tumors were also absent in the 10
WT-1, 16 Mut-1, 38 Mut-2 and 8 Mut-3 animals that were
mice heterozygous at the p53 locus. All of the Mut-1 and
Mut-2 mice heterozygous for p53 were observed for at
least 9 months, and 17 were observed for 13 to 14
months.
Figure 2
β-catenin transgenic protein expression (A) A Western 
blot of total protein extracts from mouse cerebella probed 
with anti-FLAG antisera shows high levels of transgenic pro-
tein expression in one wild-type human β-catenin line (WT-
1) and two stabilized mutant β-catenin lines (Mut-1, Mut-2). 
Lower expression is detected in the WT-2 wild-type and 
Mut-3 mutant lines. No expression is seen in the non-trans-
genic (NT) negative control lane. (B) A Western blot of 
mouse cerebellar protein divided into cytoplasmic (C) and 
nuclear (N) fractions and probed with an antibody recogniz-
ing endogenous murine as well as transgenic human β-cat-
enin. Extracts from the high-expressing mutant lines Mut-1 
and Mut-2 show elevated levels of cytoplasmic and nuclear 
protein in comparison to non-transgenic siblings. Antibody 
recognizing the cytoplasmic anti-heat shock protein 90 KDa 
(HSP90) controls for fractionation and loading.
Transgenic β-catenin
GAPDH
A. NT     Wt-1   Wt-2   Mut-1  Mut-2  Mut-3
B. Mut-1             NT              Mut-2              NT
C        N        C        N        C        N        C    N
Total 
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Figure 3
Nuclear β-catenin in the cerebellum and cortex of transgenic mice (A) While strong β-catenin immunoreactivity is 
present in the cellular processes making up the cerebellar glomeruli (arrow), no β-catenin is detected immunohistochemically 
in the blue hematoxilin-stained nuclei of internal granule layer (IGL) neurons of non-transgenic animals. (B) Many IGL neuronal 
nuclei contain β-catenin in Mut-1 transgenic animals. Scattered molecular layer neurons also have nuclear β-catenin (arrow), 
but Purkinje cell nuclei are negative (arrowhead). (C) In non-transgenic animals cerebral cortical neurons and glia do not con-
tain nuclear β-catenin. (D) Many small to medium sized cortical neuronal nuclei are immunopositive for β-catenin (arrows). 
Original magnification for all images 600X.
Table 1: Phenotypic Analysis of β-catenin Transgenic Mice.
Type Alive at 9 m.o. Dead by 9 m.o. Kinked Tails
Mut-1 27 6 1
Mut-2 32 4 0
Mut-3 10 3 6
Wt-1 8 0 0
Wt-2 27 3 0
NT 26 6 0BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/33
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Discussion
We have created transgenic mice expressing either wild-
type or mutant human β-catenin in differentiated neurons
and glia of the CNS. The mutant gene encodes β-catenin
protein stabilized by alteration of a phosphorylation site
required for proteosomal degradation. In the transgenic
line expressing high levels of human wild-type β-catenin,
significant amounts of FLAG epitope-tagged protein were
detected, however overall β-catenin levels were only
slightly increased, suggesting the mechanisms that nor-
mally regulate β-catenin level were able to compensate for
the addition of the human transgenic protein. In contrast,
expression of S37F mutant β-catenin resulted in a 50–
100% increase in overall CNS β-catenin protein levels. Ex-
pression of the transgene seemed to be higher in selected
neuronal populations. β-catenin nuclear translocation
was detected in a subset of hippocampal, cortical and cer-
ebellar neurons normally lacking nuclear protein, consist-
ent with activation of the canonical Wnt pathway in these
cells.
Two lines of evidence suggest that the stabilized β-catenin
protein in our mice is biologically active and promotes
Wnt signaling. First, co-transfection of the cDNA used to
make our transgenic mice and the TOPFLASH Wnt path-
way reporter plasmid into DAOY medulloblastoma cells
resulted in over forty-fold induction of reporter activity.
Similar results were reported for this FLAG epitope-tagged
mutant in other cell lines [26]. Second, the tail kinking
and "waltzing" phenotypes in our transgenic animals ex-
pressing stabilized human β-catenin are highly similar to
those seen in Fused mice [29]. Fused encodes the murine
Axin homologue, and mutation of this gene results in ac-
tivation of Wnt signaling [30]. The tail kinking in our an-
imals presumably results from low level expression of the
mutant transgene in utero during vertebral patterning. The
circling behavior could be due either to ongoing aberrant
Wnt activity in the adult brain, or to subtle developmental
defects that are not easily detectable microscopically. We
observed the tail and behavioral phenotypes in multiple
transgenic lines, suggesting they are not caused by disrup-
tion of an endogenous gene by transgene integration.
Our Western blot analysis showed that transgenic protein
was expressed in the cortex and cerebellum from the ear-
liest time point assayed, six weeks post-gestation, through
12 months of age. As has been previously reported, in
non-transgenic animals we detected nuclear β-catenin
only in the thalamus and other deep grey matter structures
[31]. In transgenic lines expressing mutant, stabilized pro-
tein, immunohistochemical analysis revealed nuclear β-
catenin in both internal granule layer (IGL) and molecu-
lar layer neurons of the cerebellum. Cortical neurons and
hippocampal granule and pyramidal cells also contained
nuclear β-catenin in transgenic but not non-transgenic an-
imals. We also examined the subcellular localization of
mutant β-catenin in newborn transgenic mice. In these P0
animals we failed to identify nuclear β-catenin in the pro-
liferative cells of the cerebellar external granule cell layer
or in periventricular neuroblasts. Thus in our transgenic
animals, aberrant Wnt activation appears to be limited to
mature, postmitotic neurons.
Wnt activation in the adult hippocampus, cortex and cer-
ebellum did not result in tumors or other CNS malforma-
tions. Strain effects are unlikely to have played a role in
this lack of a neoplastic phenotype, as mice with the same
background as the one we used have previously been
shown to develop medulloblastomas [12]. We further at-
tempted to induce CNS tumors by abrogating p53 func-
tion in conjunction with transgenic β-catenin expression.
The rational for this approach was the markedly increased
incidence of medulloblastomas seen in PTCH heterozy-
gotes deficient for p53, and the enhanced intestinal ade-
noma phenotype of p53 null, APC heterozygous Min mice
[12,32]. We did not observe any significant phenotypic
changes in the CNS of β-catenin transgenic animals heter-
ozygous or homozygous for disruption of the p53 locus.
However, most of the β-catenin transgenic mice hetero-
zygous for p53 were followed for only 9 months, and it is
possible that some of these mice could develop tumors at
a later age.
In transgenic mice expressing mutant β-catenin in the
breast or colon, protein levels similar to those we describe
are sufficient to promote abnormal differentiation and tu-
mors. Harada and colleagues documented intestinal poly-
Figure 4
Tail kinking in a Mut-3 transgenic mouse expressing 
stabilized β-cateninBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/33
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posis in β-catenin transgenic mice with a less than 2-fold
increase in β-catenin protein level in the polyps [33]. The
authors point out that because the transgene was only ex-
pressed in a fraction of cells in this tissue, protein levels
are likely higher in some epithelial cells. A similar expla-
nation can be applied to our mice, in which nuclear trans-
location of β-catenin was only detected in a fraction of
neurons. A 2-fold to 3-fold increase of β-catenin level in
the mammary glands of transgenic mice also results in ab-
errant differentiation and tumors [34,35]. Thus while it is
possible that a greater than 2-fold increase in β-catenin
level would have a neoplastic effect on adult neurons, ev-
idence from other transgenic models suggests the in-
creased protein level in our mice could be sufficient for
tumor promotion. Overall, our data suggest that activa-
tion of Wnt signaling in adult cerebellar and cortical neu-
rons may not be sufficient for formation of
medulloblastoma/PNET.
Recent experiments by Fults and colleagues support the
idea that stabilized β-catenin expression in the postnatal
CNS is not sufficient to initiate tumor formation [36]. Us-
ing the RCAS-TVA system they showed that overexpres-
sion of c-myc, but not of activated β-catenin, promoted
the proliferation of neural progenitor cells in vivo and in
vitro. In their in vivo experiments expression was initiated
in nestin positive cells postnatally via injection of β-caten-
in stabilized by a point mutation in codon 37.
Activation of the Wnt pathway in primitive neuroepitheli-
al cells in utero results in a quite different outcome. Chenn
and Walsh recently created transgenic mice in which β-
catenin stabilized by an amino-terminal truncation was
expressed in subventricular zone precursor cells in utero
under control of the nestin promoter [22]. Brains from
these transgenic embryos contained increased numbers of
periventricular neuroepithelial cells because a greater
number of the precursors re-entered the cell cycle after mi-
tosis. The cerebellar phenotype in these mice was not re-
ported, and it is not clear if the aberrantly proliferating
neuroepithelial precursors in their mice represent a pre-
neoplastic population. These transgenic lines express β-
catenin lacking the entire amino-terminal inhibitory do-
main, and this truncating β-catenin mutation they may
have an increased or changed activity compared to our
construct. Alternatively, the contrast between the in utero
cortical changes reported by Chenn and Walsh and the
lack of a CNS phenotype in our mice or those of Fults
could indicate that the developmental stage of the neu-
roepithelial cells in which stabilized β-catenin is ex-
pressed is critical.
In summary, we have expressed wild-type and mutant,
stabilized human β-catenin in differentiated neurons and
glia of adult transgenic mice. While expression of wild-
type human protein does not significantly alter overall β-
catenin levels, stabilized protein accumulates in hippoc-
ampal, cortical and cerebellar neurons and translocates
into their nuclei. The tail kinking in these mice is highly
similar to the phenotype seen in Axin mutants with acti-
vated Wnt signaling, indicating the β-catenin protein ex-
pressed in our transgenic mice is functional. However, no
tumors, pre-neoplastic changes or other CNS morpholog-
ic alterations were detected, suggesting that postnatal ab-
errant Wnt activation is not sufficient to induce CNS
tumorigenesis in mice. It is possible, however, that higher
β-catenin protein levels, or expression in undifferentiated
precursor cells in utero, would result in tumor formation.
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